According to the Clinical Trials Registry (https://clinicaltrials.gov/ct2/history/NCT04614948?V_14=View#StudyPageTop) ENSEMBLE 2 is expecting completion in May, 2022. The study design is also two doses of placebo vs. two doses of Ad26.COV2.S (not 1 vs. 2 doses as I personally would have expected). The two-placebo subjects would receive a single dose of the vaccine at unblinding, but that page doesn't state when unblinding would occur.
I am guessing you were expecting preliminary data by now?
According to the Clinical Trials Registry (https://clinicaltrials.gov/ct2/history/NCT04614948?V_14=View#StudyPageTop) ENSEMBLE 2 is expecting completion in May, 2022. The study design is also two doses of placebo vs. two doses of Ad26.COV2.S (not 1 vs. 2 doses as I personally would have expected). The two-placebo subjects would receive a single dose of the vaccine at unblinding, but that page doesn't state when unblinding would occur.
I am guessing you were expecting preliminary data by now?